Pancreatic Cancer Research

ResearcherNanjing Drum Tower HospitalActive in the last 2 years

Chao Yan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6029-224X; OpenAlex author ID A5022572701. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 2 papers

Papers 8

  1. SP1-Mediated Glycolytic Reprogramming Promotes Tumorigenesis and Progression in Pancreatic Cancer. Co-author DOI 10.1002/advs.202510071↗
  2. CD44 identified as a diagnostic biomarker for highly malignant CA19-9 negative pancreatic cancer. Last author DOI 10.1016/j.canlet.2025.217713↗
  3. Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis. Co-author DOI 10.1038/s41467-023-40727-7↗
  4. Hesperadin suppresses pancreatic cancer through ATF4/GADD45A axis at nanomolar concentrations. Co-author DOI 10.1038/s41388-022-02328-4↗
  5. Sauchinone inhibits hypoxia-induced epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma cells through the Wnt/β-catenin pathway. Last author DOI 10.1097/cad.0000000000000956↗
  6. Antitumour indolequinones: synthesis and activity against human pancreatic cancer cells. Co-author DOI 10.1039/c4ob00711e↗
  7. Antitumor indolequinones induced apoptosis in human pancreatic cancer cells via inhibition of thioredoxin reductase and activation of redox signaling. Co-author DOI 10.1124/mol.111.076091↗
  8. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 9… Co-author DOI 10.1124/jpet.110.176438↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jiatong Tang · 2 shared papers, 2025 · strength 0.39
  2. Neng Tang · 2 shared papers, 2025 · strength 0.39
  3. Hexing Hang · 2 shared papers, 2025 · strength 0.39
  4. Hao Cheng · 2 shared papers, 2025 · strength 0.39
  5. Ying Lv · 2 shared papers, 2022–2023 · strength 0.26
  6. Hao Wu · 2 shared papers, 2022–2023 · strength 0.26
  7. Shanshan Shen · 2 shared papers, 2022–2023 · strength 0.26
  8. Shu Zhang · 2 shared papers, 2022–2023 · strength 0.26
  9. Xiaoping Zou · 2 shared papers, 2022–2023 · strength 0.26
  10. Yixuan Zhang · 1 shared paper, 2025 · strength 0.20
  11. Wei Wei · 1 shared paper, 2025 · strength 0.20
  12. Yudong Qiu · 1 shared paper, 2025 · strength 0.20
  13. Yuan Qiao · 1 shared paper, 2020 · strength 0.19
  14. Linxi Zhu · 1 shared paper, 2025 · strength 0.19
  15. Yudong Qiu · 1 shared paper, 2025 · strength 0.19
  16. Qi Li · 1 shared paper, 2025 · strength 0.19
  17. Xiao Fu · 1 shared paper, 2025 · strength 0.19
  18. Zhenghua Cai · 1 shared paper, 2025 · strength 0.19
  19. Lei Wang · 1 shared paper, 2023 · strength 0.14
  20. Yixuan Zhang · 1 shared paper, 2023 · strength 0.14
  21. Dongming Zhu · 1 shared paper, 2023 · strength 0.14
  22. Lei Wang · 1 shared paper, 2022 · strength 0.13
  23. Yixuan Zhang · 1 shared paper, 2022 · strength 0.13
  24. David M. Siegel · 3 shared papers, 2011–2014 · strength 0.12
  25. David Ross · 3 shared papers, 2011–2014 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.